References
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
- WHO Health Emergency. Dashboard. WHO (COVID-19) Homepage [Internet]. WHO Homepage. 2020 [cited 2020 May 31]. Available from: http://covid19.who.int/
- Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Heal. 2020;25:278–280.
- Bietsch K, Williamson J, Reeves M. Family planning during and after the West African Ebola Crisis. Stud Fam Plann. 2020;51:71–86.
- Webster P. Virtual health care in the era of COVID-19. Lancet. 2020;395:1180–1181.
- British Association of Sexual Health and HIV. Contingency planning for out-patient Genitourinary Medicine, Contraception and Sexual Health Services (including online) and HIV services [Internet]. 2020. Available from: https://www.bashh.org/news/news/updated-covid-19-guidance-provision-of-sexual-services-to-the-community/
- Tang K, Gaoshan J, Ahonsi B. Sexual and reproductive health (SRH): a key issue in the emergency response to the coronavirus disease (COVID- 19) outbreak. Reprod Health. 2020;17:59.
- Short M, Bitzer J, Rowlands S. Testing times. Eur J Contracept Reprod Heal Care. 2020;25:1–2.
- Bearak J, Popinchalk A, Alkema L, et al. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Heal. 2018;6:e380–e389.
- Committee Opinion No. 654: reproductive life planning to reduce unintended pregnancy. Obstet Gynecol. 2016;127:e66–9.
- Bellizzi S, Mannava P, Nagai M, et al. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle-income countries. Contraception. 2020;101:26–33.
- Cleland J, Conde-Agudelo A, Peterson H, et al. Contraception and health. Lancet. 2012;380:149–156.
- Thomas CM, Cameron S. Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC. BMJ Open. 2013;3:e003815.
- Le HH, Connolly MP, Bahamondes L, et al. The burden of unintended pregnancies in Brazil: a social and public health system cost analysis. Int J Womens Health. 2014;6:663–670.
- Hall KS, Samari G, Garbers S, et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet. 2020;395:1175–1177.
- Riley T, Sully E, Ahmed Z, et al. Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries. Int Perspect Sex Reprod Health. 2020;46:73–76.
- da Silva ATM, Menezes CL, de Sousa Santos EF, et al. Referral gynecological ambulatory clinic: principal diagnosis and distribution in health services. BMC Womens Health. 2018;18:8.
- Guilhem D, Azevedo AF. Brazilian public policies for reproductive health: family planning, abortion and prenatal care. Dev World Bioeth. 2007;7:68–77.
- Ministério da Saúde. Relação Nacional de Medicamentos Essenciais: rename 2020. [Internet]. Brasília - DF; 2019. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/relacao_medicamentos_rename_2020.pdf
- Peipert JF, Madden T, Allsworth JE, et al. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012;120:1291–1297.
- World Health Organization. Contraception/Family planning and COVID-19 [Internet]. 2020 [cited 2020 May 1]. Available from: https://www.who.int/news-room/q-a-detail/contraception-family-planning-and-covid-19
- World Health Organization. Medical eligibility criteria for contraceptive use. Geneva. 2015.
- Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2016;65:1–103.
- Nanda K, Lebetkin E, Steiner MJ, et al. Contraception in the Era of COVID-19. Glob Heal Sci Pract. 2020;8:1–3.
- United Nations Population Fund. Sexual and reproductive health and rights: modern contraceptives and other medical supply needs, including for COVID-19 prevention, protection and response. [Internet]. 2020. Available from: https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_Preparedness_and_Response_-_UNFPA_Interim_Technical_Briefs_Contraceptices_and_Medical_Supplies_23_March.pdf
- Kinyanjui N COVID-19: A double burden for women in conflict areas, on the frontline [Internet]. 2020 [cited 2020 May 1]. Available from: https://www.un.org/africarenewal/web-features/coronavirus/covid-19-double-burden-women-conflict-areas-frontline
- Sorpreso ICE, Soares Júnior JM, Baracat EC. Sexually vulnerable women: could reversible long-lasting contraception be the solution? Rev Bras Ginecol E Obstet. 2015;37:395–396.
- Bustamante LHU, Leclerc E, Mari JD, et al. It is time to prepare mental health services to attend to migrants and refugees. Rev Bras Psiquiatr. 2016;38:263–264.
- Faculty of Sexual and Reproductive Healthcare. FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak [Internet]. 2020 [cited 2020 May 2]. Available from: https://www.fsrh.org/documents/fsrh-ceu-clinical-advice-to-support-provision-of-effective/
- Faculty of Sexual and Reproductive Healthcare. FSRH guidance for contraceptive provision after changes to Covid-19 lockdown May 2020 [Internet]. 2020 [cited 2020 May 30]. Available from: https://www.fsrh.org/documents/fsrh-guidance-contraceptive-provision-changes-covid-lockdown/.
- Comissão Nacional de Anticoncepção da Febrasgo. Anticoncepção durante a pandemia por COVID-19 [Internet]. 2020 [cited 2020 May 3]. Available from: https://www.febrasgo.org.br/en/covid19/item/1002-anticoncepcao-durante-a-pandemia-por-covid-19
- The American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for Obstetrician–Gynecologists, Gynecology [Internet]. 2020 [cited 2020 May 30]. Available from: https://www.acog.org/clinical-information/physician-faqs/covid19-faqs-for-ob-gyns-gynecology
- Bahamondes L, Faundes A, Sobreira-Lima B, et al. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005;72:337–341.
- United Nations Development Programme; United Nations Population Fund; World Health Organization. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56:341–352.
- Ti AJ, Roe AH, Whitehouse KC, et al. Effectiveness and safety of extending intrauterine device duration: a systematic review. Am J Obstet Gynecol. 2020;S0002–9378: 30021–1.
- Bahamondes L, Fernandes A, Bahamondes MV, et al. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil. Contraception. 2018;97:205–209.
- McNicholas C, Swor E, Wan L, et al. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216:586.e1–586.e6.
- Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–2498.
- Thaxton L, Lavelanet A. Systematic review of efficacy with extending contraceptive implant duration. Int J Gynaecol Obstet. 2019;144:2–8.
- National Institutes of Health (NIH). COVID-19 Treatment Guidelines [Internet]. 2020 [cited 2020 Apr 30]. Available from: https://www.covid19treatmentguidelines.nih.gov/introduction/
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — preliminary Report. N Engl J Med. 2020. DOI:10.1056/NEJMoa2007764.
- ClinicalTrials.gov [Internet]. 2020 [cited 2020 Apr 30]. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19
- Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother. 1996;37(Suppl C):133–142.
- Fischer JH, Sarto GE, Habibi M, et al. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. Antimicrob Agents Chemother. 2012;56:715–724.
- A study of baricitinib and birth control pills in healthy females [Internet]. 2013 [cited 2020 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01896726
- Costanzo G, Firinu D, Losa F, et al. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020;12:1–3.
- Du Y-X, Chen X-P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020:1–6.
- Jacomini LCL, da Silva NA. Interações medicamentosas: uma contribuição para o uso racional de imunossupressores sintéticos e biológicos. Rev Bras Reumatol. 2011;51:168–174.
- Hendrix CW, Jackson KA, Whitmore E, et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004;75:464–475.
- Lazorwitz A, Seale R, Davis A, et al. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception. 2020;S0010–7824:30126–30128.
- U.S. Food and Drug Administration. Leflunomide: package inserts. [Internet]. 2010 [cited 2020 May 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020905s020lbl.pdf.
- Landolt NK, Bunupuradah T, Kosalaraksa P, et al. High variability of hormonal levels and no clinically relevant interaction between ethinyl estradiol, desogestrel and lopinavir/ritonavir in a small sample of HIV-positive adolescents. J Acquir Immune Defic Syndr. 2016;72:507–512.
- Luque AE, Cohn SE, Park J-G, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015;59:2094–2101.
- Vieira CS, Bahamondes MV, de Souza RM, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. J Acquir Immune Defic Syndr. 2014;66:378–385.
- Slayter KL, Ludwig EA, Lew KH, et al. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996;59:312–321.
- Sanofi-aventis Canada Inc. Sarilumab Product Monograph. [Internet]. 2017 [cited 2020 May 2]. p. 7. Available from: http://products.sanofi.ca/en/Kevzara-en.pdf
- Zhang X, Rowell L, Fettner S, et al. Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis. Int J Clin Pharmacol Ther. 2014;52:27–38.
- Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106:1289–1294.
- Anderson FAJ, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–16.
- Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020. DOI:10.1111/jth.14849
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;S0735–1097: 35008–7.
- Liu X, Liu C, Chen X, et al. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. Interact Cardiovasc Thorac Surg. 2016;23:538–543.
- Asociación Española para el Estudio de la Menopausia; Sociedad Española de Ginecología y Obstetricia; Sociedad Española de Trombosis y Hemostasia. Riesgo Tromboembólico en la pandemia de COVID-19 y tratamiento hormonal en mujeres perimenopausicas y postmenopausicas. [Internet]. 2020 [cited 2020 May 8]. p. 1–9. Available from: https://www.covid-19.seth.es/riesgo-tromboembolico-en-la-pandemia-de-covid-19-y-tratamiento-hormonal-en-mujeres-perimenopausicas-y-postmenopausicas/
- Ramírez I, De la Viuda E, Baquedano L, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemos. Maturitas. 2020;137:57–62..
- Collège National des Enseignants de Gynécologie Médicale; L’Unité d’Hémostase Clinique de Cochin. Prévention du risque thromboembolique veineux chez les femmes COVID + non hospitalisées utilisant un traitement hormonal (Contraception, Traitement hormonal de ménopause, Tamoxifène) [Internet]. 2020 [cited 2020 May 30]. Available from: http://www.cngof.fr/coronavirus-go-cngof/apercu?path=HEMOSTASE%2B-%2BRISQUE%2BDE%2BMTE%252FHemostase-PreventionMVTECOVIDHormones.pdf&i=36239
- de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3): Art. no. CD010813.
- Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94:678–700.
- Sánchez LA, Pérez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril. 2007;87:712–714.
- Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012;10:992–997.
- Stelzig KE, Canepa-Escaro F, Schiliro M, et al. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280-L1281.